Related Experiment Videos
Management of the hypertensive patient with coronary artery disease
1University of Alabama at Birmingham, 35294, USA.
Insights
Hypertension and coronary artery disease (CAD) increase cardiovascular risks. Optimizing treatment timing with long-acting medications during critical hours may reduce patient morbidity and mortality.
Area of Science:
- Cardiology
- Pharmacology
- Chronobiology
Background:
- Hypertension is a global cardiovascular disease risk factor, often underdiagnosed and undertreated.
- Hypertension, especially with other factors, elevates coronary artery disease (CAD) risk.
- CAD increases morbidity, mortality, and treatment complexity.
Purpose of the Study:
- To explore the role of chronobiology in managing hypertension and CAD.
- To identify optimal therapeutic strategies for hypertensive patients with CAD.
Main Methods:
- Review of existing literature on hypertension, CAD, and cardiovascular event timing.
- Analysis of chronobiological patterns in cardiovascular events.
- Evaluation of long-acting antihypertensive agents.
Main Results:
- Cardiovascular events exhibit distinct daily patterns (chronobiology).
- High plasma drug concentrations during critical hours are associated with reduced risk.
- Long-acting agents can maintain therapeutic levels during these critical periods.
Conclusions:
- Chronobiology offers a strategic approach to hypertension management in CAD patients.
- Tailoring medication timing and using long-acting agents can mitigate cardiovascular risk.
- Optimized pharmacotherapy based on circadian rhythms may improve patient outcomes.
Abstract:
Hypertension, a major risk factor for cardiovascular disease worldwide, remains inadequately diagnosed and treated, particularly in certain at-risk populations. Hypertension, often in association with other factors, increases the risk for the development of coronary artery disease (CAD). In turn, CAD increases the risk for related morbidity and mortality and presents treatment challenges. The chronobiology of many cardiovascular events offers a pathway for selecting optimal therapy for the hypertensive patient with CAD. Choosing a long-acting agent that achieves high plasma drug levels during critical hours may reduce the risk for cardiovascular morbidity and mortality.